|
Autoimmune Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165.
|
31318208 |
2019 |
|
Autoimmune Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
The search for inhibitors of the Janus kinase family (JAK1, JAK2, JAK3 and TYK2) has been ongoing for several decades and has resulted in a number of JAK inhibitors being approved for use in patients, such as tofacitinib for the treatment of autoimmune diseases such as Rheumatoid Arthritis (RA).
|
31288716 |
2019 |
|
Autoimmune Diseases
|
0.200 |
GeneticVariation
|
group |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Autoimmune Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
Tyrosine Kinase 2 (TYK2) Allosteric Inhibitors To Treat Autoimmune Diseases.
|
31603320 |
2019 |
|
Autoimmune Diseases
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Our MD results provided information, at atomic level, on the consequences of the Pro1104 to Ala substitution on the structure and dynamics of the kinase domain of Tyk2 and suggested reduced enzymatic activity of the resulting protein variant due to stabilization of inactive conformations, thus adding to knowledge towards the elucidation of the protection mechanism against autoimmune diseases associated with this point mutation.
|
30423093 |
2018 |
|
Autoimmune Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841).
|
30113844 |
2018 |
|
Autoimmune Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
Single nucleotide polymorphisms (SNPs) in the GLI-similar 3 (GLIS3) and tyrosine kinase 2 (TYK2) genes have been associated with various autoimmune diseases.
|
28846454 |
2017 |
|
Autoimmune Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
TYK2 is a common genetic risk factor for several autoimmune diseases.
|
26338038 |
2016 |
|
Autoimmune Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
Our data revealed a protective homozygous effect that defined a signaling optimum between autoimmunity and immunodeficiency and identified TYK2 as a potential drug target for certain common autoimmune disorders.
|
27807284 |
2016 |
|
Autoimmune Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
Together, our results demonstrate the role of TYK2 in the pathogenesis of RA, SLE and IBD, and provide supporting evidence for TYK2 as a promising drug target for the treatment of autoimmune diseases.
|
25849893 |
2015 |
|
Autoimmune Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
In addition, Tyk2-mediated signaling promoted the production of autoimmune-associated components, which is implicated in the pathogenesis of autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis.
|
24654603 |
2014 |
|
Autoimmune Diseases
|
0.200 |
GeneticVariation
|
group |
BEFREE |
In this study, we characterized two rare Tyk2 variants, I684S and P1104A, which have been associated with susceptibility to autoimmune disease.
|
23359498 |
2013 |
|
Autoimmune Diseases
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Furthermore, numerous genome-wide association studies in humans propose a link between TYK2 genetic variants and several autoimmune diseases, inflammatory diseases and tumours.
|
21622231 |
2011 |
|
Autoimmune Diseases
|
0.200 |
AlteredExpression
|
group |
BEFREE |
The modulation of tyrosine kinase 2 activity might therefore represent a new therapeutic approach for the treatment of autoimmune diseases.
|
21354972 |
2011 |
|
Autoimmune Diseases
|
0.200 |
GeneticVariation
|
group |
LHGDN |
We suggest that mutations in the JAK1 and Tyk2 genes may be identified as initial molecular defects in human cancers and autoimmune diseases.
|
16239216 |
2005 |
|
Autoimmune Diseases
|
0.200 |
GeneticVariation
|
group |
BEFREE |
We suggest that mutations in the JAK1 and Tyk2 genes may be identified as initial molecular defects in human cancers and autoimmune diseases.
|
16239216 |
2005 |